Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | HNF4A | P41235 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706042 | 0.85 | PTGES (0.43) | PTGESPTPN11RXFP1FFAR1HNF4A | |
| SCHEMBL4310561 | 0.84 | GABRA5 (0.43) | RAB9APTPN11RXFP1MEN1MAPT | |
| SCHEMBL4300793 | 0.83 | KCNQ4 (0.45) | RAB9ANPC1PTPN11RXFP1MEN1 | |
| SCHEMBL7043137 | 0.79 | PTPN11 (0.59) | RAB9ANPC1PTPN11MEN1MAPT | |
| SCHEMBL5557083 | 0.79 | KCNQ4 (0.47) | PTPN11CYP17A1 | |
| SCHEMBL5869163 | 0.78 | NPC1 (0.48) | RAB9ANPC1MAPTHTTPOLB | |
| SCHEMBL23288019 | 0.78 | RXFP1 (0.42) | RAB9ANPC1PTPN11RXFP1MAPT | |
| SCHEMBL15614546 | 0.78 | MAPT (0.51) | RXFP1MEN1MAPTHTTKMT2A | |
| SCHEMBL661640 | 0.77 | RAB9A (0.56) | RAB9ANPC1RXFP1MEN1MAPT | |
| SCHEMBL5869021 | 0.77 | GRM5 (0.40) | RXFP1FFAR1FFAR4CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1939204-B3 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2022-08-24 | — | — | EP | disclosed |
| US-9040693-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-1939204-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1939204-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | SHBG, CYP19A1, NR5A1 | VCP 4239/4885RAB9A 2828/4885NPC1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.